MGNX vs MRNA
MGNX: Clinical-stage biopharmaceutical company developing innovative antibody-based cancer therapeutics using proprietary DART, TRIDENT, and ADC platforms. MRNA: Moderna is an unprofitable mRNA vaccine and therapeutic company pivoting from peak COVID revenues with a diversified pipeline facing intense competition and declining sales.
Side-by-side fundamentals
| Metric | MGNX | MRNA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.30 | $58.07 | |
| Market cap as of 2026-07-23 | $289M | $22.9B | |
| PEG as of 2026-07-23 | -0.16 | n/a | |
| Net margin as of 2026-07-23 | -44.8% | -143.6% | MGNX higher |
| Gross margin as of 2026-07-23 | +74.5% | +35.0% | MGNX higher |
| Operating margin as of 2026-07-23 | -40.5% | -153.3% | MGNX higher |
| ROE as of 2026-07-23 | -147.8% | -36.7% | MRNA higher |
| ROA as of 2026-07-23 | -28.4% | -26.6% | MRNA higher |
| Debt / equity as of 2026-07-23 | 3.24 | 0.09 | MRNA lower |
| Revenue growth (YoY) as of 2026-07-23 | +2.0% | -30.0% | MGNX higher |
| Revenue CAGR (3y) SEC XBRL | -0.5% | -53.4% | MGNX higher |
| Beta as of 2026-07-23 | 1.19 | 0.88 | |
| 1-year return as of 2026-07-22 close | +179.2% | +77.4% | MGNX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.